Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullén A, Yachnin J, Nilsson S, Panaretakis T.
Kharaziha P, et al. Among authors: lennartsson l.
Oncotarget. 2015 Aug 28;6(25):21740-54. doi: 10.18632/oncotarget.3226.
Oncotarget. 2015.
PMID: 25844599
Free PMC article.
Clinical Trial.